Literature DB >> 10915221

Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines.

J Beilin1, E M Ball, J M Favaloro, J D Zajac.   

Abstract

The action of androgens is essential for the development of benign prostatic hyperplasia and carcinoma of the prostate. The androgen receptor is a ligand-dependent nuclear transcription factor. The transcriptional activation domain of the androgen receptor gene contains a polymorphic CAG repeat sequence. A shorter CAG repeat sequence within the normal range has been reported to be associated with increased risk of prostate cancer and symptomatic benign prostatic hyperplasia. Here, we examine the in vitro transcriptional activity of the androgen receptor (AR) with different numbers of CAG repeats within the normal range in a number of different cell lines of prostatic (LNCaP, PC3) and non-prostatic (COS-1, MCF7) origin. We utilize a luciferase reporter driven by the rat probasin promoter (-286/+28) containing two androgen receptor binding sites. Transcriptional activation of the androgen responsive reporter was observed to be greater with the AR containing 15 vs 31 CAG repeats in COS-1 cells (123.2+/-16.6 vs 78.2+/-10.9, P value 0.01) and the well differentiated prostate cancer cell line LNCaP (103.4+/-17.7 vs 81.4+/-7.7, P value 0.045). No difference was observed in the poorly differentiated prostate cancer cell line, PC3 (106.9+/-21.9 vs 109. 6+/-21.4, P>0.5) or the breast cancer cell line MCF7 (120.4+/-39.4 vs 103.1+/-23.1, P value >0.5). Dose-response experiments with varying quantities of ligand (0.01, 0.1, 1 and 10 nM dihydrotestosterone) or AR cDNA did not demonstrate significant differences in transactivation of the androgen responsive reporter in PC3 cells by the different AR constructs. This suggests that the lack of influence of CAG number in this prostatic cell line is not related to dose of ligand or quantity of androgen receptor. Western immunoblot analysis of androgen receptor protein in transiently transfected COS-1 cells did not demonstrate a difference in the expression of the androgen receptor protein with different numbers of CAG repeats following incubation in the presence or absence of androgen. Gel shift assay did not demonstrate increased DNA binding by androgen receptor with a shorter CAG repeat sequence. These experiments using a relatively androgen- and prostate-specific reporter provide evidence for an inverse relationship between androgen receptor transcriptional activity and the number of CAG repeats in the transcriptional activation domain. The effect of CAG repeat number was cell specific suggesting the involvement of accessory factors expressed differentially between different cell lines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915221     DOI: 10.1677/jme.0.0250085

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  54 in total

1.  A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Authors:  Sara Lindström; Jing Ma; David Altshuler; Edward Giovannucci; Elio Riboli; Demetrius Albanes; Naomi E Allen; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Stephen J Chanock; Alison M Dunning; Heather Spencer Feigelson; J Michael Gaziano; Christopher A Haiman; Richard B Hayes; Brian E Henderson; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Loic Le Marchand; Carmen Martínez; Kim Overvad; Afshan Siddiq; Meir Stampfer; Pär Stattin; Daniel O Stram; Michael J Thun; Dimitrios Trichopoulos; Rosario Tumino; Jarmo Virtamo; Stephanie J Weinstein; Meredith Yeager; Peter Kraft; Matthew L Freedman
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

2.  Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia.

Authors:  Justine A Ellis; Katrina J Scurrah; Joanna E Cobb; Sophie G Zaloumis; Anna E Duncan; Stephen B Harrap
Journal:  Hum Genet       Date:  2007-01-26       Impact factor: 4.132

3.  Effects of testosterone replacement therapy on bone metabolism in male post-surgical hypogonadotropic hypogonadism: focus on the role of androgen receptor CAG polymorphism.

Authors:  G Tirabassi; N delli Muti; A Gioia; A Biagioli; A Lenzi; G Balercia
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

4.  Direct detection of the AR-E211 G > A gene polymorphism from blood and tissue samples without DNA isolation.

Authors:  Silvie Reptova; Katerina Smesny Trtkova; Zdenek Kolar
Journal:  Pathol Oncol Res       Date:  2014-02-01       Impact factor: 3.201

Review 5.  Epidemiology of Prostate and Testicular Cancer.

Authors:  Pauline Filippou; James E Ferguson; Matthew E Nielsen
Journal:  Semin Intervent Radiol       Date:  2016-09       Impact factor: 1.513

6.  Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study.

Authors:  Matthew L Freedman; Celeste L Pearce; Kathryn L Penney; Joel N Hirschhorn; Laurence N Kolonel; Brian E Henderson; David Altshuler
Journal:  Am J Hum Genet       Date:  2004-11-29       Impact factor: 11.025

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

8.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

9.  Androgen receptor CAG polymorphism and sporadic and early-onset prostate cancer among Mexican men.

Authors:  Rocío Gómez; Luisa Torres-Sánchez; Rafael Camacho-Mejorado; Ana I Burguete-García; Ruth Argelia Vázquez-Salas; Gabriela A Martínez-Nava; Carla Santana; Gino Noris
Journal:  J Hum Genet       Date:  2016-05-19       Impact factor: 3.172

10.  Androgen receptor status predicts response to chemotherapy, not risk of breast cancer in Indian women.

Authors:  Pranjal Kulshreshtha; Anurupa Chakraborty; Lc Singh; Ashwani K Mishra; Dinesh Bhatnagar; Sunita Saxena
Journal:  World J Surg Oncol       Date:  2010-08-04       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.